

TAB1 Recombinant Mouse mAb

TAB1 Recombinant Mouse mAb

Catalog # AP94438

Product Information

Application	WB
Reactivity	Human, Mouse
Predicted	Rat
Host	Mouse
Clonality	Recombinant
Physical State	Liquid
Isotype	IgG1, Kappa
Purity	affinity purified by Protein G
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SIMILARITY	Contains 1 PP2C-like domain.
SUBUNIT	Interacts with XIAP and BIRC7. Interacts with TRAF6 and MAP3K7; during IL-1 signaling. Identified in the TRIKA2 complex composed of MAP3K7, TAB1 and TAB2.
Post-translational modifications	Monoubiquitinated. Deubiquitinated by Y.enterocolitica YopP.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	TAB1 was identified as a regulator of the MAP kinase kinase kinase TAK1/MAP3K7, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta and members of the Toll IL 1R (TIR) superfamily, thus acting as an intermediate in both proliferative and innate and adaptive immune responses. This protein, together with either TAB2 or TAB3, activates TAK1 kinase in response to upstream signals. It has been shown that the C terminal portion of TAB1 is sufficient for binding and activation of TAK1, while a portion of the N terminus acts as a dominant negative inhibitor of TGF beta, demonstrating how this protein can function as a mediator between TGF beta receptors and TAK1.

Additional Information

Target/Specificity	Ubiquitous.
Dilution	WB=1:500-1000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Background

TAB1 was identified as a regulator of the MAP kinase kinase kinase TAK1/MAP3K7, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta and members of the Toll IL 1R (TIR) superfamily, thus acting as an intermediate in both proliferative and innate and adaptive immune responses. This protein, together with either TAB2 or TAB3, activates TAK1 kinase in response to upstream signals. It has been shown that the C terminal portion of TAB1 is sufficient for binding and activation of TAK1, while a portion of the N terminus acts as a dominant negative inhibitor of TGF beta, demonstrating how this protein can function as a mediator between TGF beta receptors and TAK1.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.